USA Change Macroaxis User Registration

Home Portfolios Solutions About Us

More ROI Blog

PortfoliosPositionsRebalanceAnalyzeOptimize Suggest Industries

US Market Closed: Feb 10, 00:55 AM 2012

NYSE 8081.25 NASDAQ 2927.23 11.37 Index Moved Up

and more..

sponsered by

Processing
Collecting necessary data for SLXP...

Salix financials and fundamentals

Companies

Sectors

Advisers

More Actions
- Equity Search
- Advanced Search
- Filter Tops
- Adviser Directory
- Suggest Portfolio
- Backtest Watchlist
- Analyze Correlations
- View Transactions
- Check Volatility
- Import Equities

48.89

Intraday

One Month

^(0.33)

0.67%

25.64

Year To Date

50.28

48.8

Trading Day

49.8084

Embed Now

Diversification Suggestion

Use Salix to protect against small markets fluctuations. The stock experiences moderate downward daily trend and can be a good diversifier

1 Month Beta vs NYSE ......... -0.43

As returns on NYSE increase, returns on owning Salix are expected to decrease at a much smaller rate. During bear market, Salix is likely to outperform the market

SLXP

NASDAQ

Salix Pharmaceuticals Ltd.

http://www.salix.com

919-862-1000

Trade Salix

Run Report

Correlation

Drugs - Generic

Market Capitalization 2.891B

Earnings Per Share 1.30

Today Lowest 48.80

Book Value Per Share 8.127

Carolyn J. Logan

Chief Officer, President, Director

Adam C. Derbyshire

Chief Financial Officer, Principal

Dr. William P. Forbes Pharm. D.

Chief Devel. Officer and VP of R&a

Dr. Lorin K. Johnson Ph.D.

Co-Founder and Chief Scientific Lia

Randy W. Hamilton

Co-Founder

Salix fundamentals

P/E	37.86	Open	49.47
P/B Ratio	6.06	Volume	222084
Sector	Healthcare	Last Close	49.22
Short Ratio	7.80	Last Traded	2/9/2012
Year High	50.28	Percent Change	0.67%
Year Low	25.64	Absolute Change	0.33
EPS	1.30	Index Membership	Not Applicable
PEG Ratio	0.94	Employees	390
Day High	49.8084	Day Low	48.80
Target Price	54.53	Current EPS	1.30
This Year EPS	2.55	Next Year EPS	2.79
Current PE	37.86	This Year PE	19.30
Next Year PE	17.64	Dividend	Not Applicable

Salix Performance

Embed Financials for Salix Pharmaceuticals Ltd.

Salix Profile

Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs for the treatment of gastrointestinal disorders in the United States.

IXIC		0.39 %
GSPC		0.15 %
NYA		0.00 %
SLXP		0.67 %

Live Sentiment

PUW

N/A

Bought over 500 shares of

PowerShares WilderHill Progrsv

6 minutes ago

for 26.32

PKN

N/A

Bought over 500 shares of

PowerShares Global Nuclear Ene

7 minutes ago

for 17.47

PZD

N/A

Bought over 500 shares of

PowerShares Cleantech

8 minutes ago

for 24.61

PIO

N/A

Bought over 500 shares of

PowerShares Global Water

14 minutes ago

for 17.85

IBB

N/A

Bought over 500 shares of

iShares Nasdaq Biotechnology

16 minutes ago

for 120.11

Salix 30-Days Moving Rating

Macroaxis Total Score

Current 30 Days Moving Rating

Estimated Market Risk

1.78

actual daily

70 %

of total potential

Expected Return

0.03

actual daily

2 %

of total potential

Risk-Adjusted Return

0.02

actual daily

1 %

of total potential

Based on monthly moving average [ change ]

Increase Risk-Adjusted return of SLXP by adding it to a well-diversified portfolio

Diversify

Salix Last Intraday

(0.33) Macroaxis: -0.33 Up

0.67%

49.22,49.22,48.89,48.89,49.8084,48.80,48.89

49.22

48.89

Latest headlines for Salix

Few days ago at www.fnno.com

Salix Pharmaceuticals Crosses Above its 10-day MA (SLXP)

Financial News Network Online - Jan 31, 2012 Salix Pharmaceuticals (NASDAQ:SLXP) shares have crossed bullishly above their 10-day moving average of $46.89 on a volume of 132K shares.

Few days ago at www.localizedusa.com

Salix Pharmaceuticals (SLXP) Downgraded by Stifel Nicolaus to "Hold"

LocalizedUSA - Jan 30, 2012 Salix Pharmaceuticals (NASDAQ: SLXP) was downgraded by Stifel Nicolaus from a ?buy? rating to a ?hold? rating in a research note issued on Monday. Salix Pharmaceuticals Up 2.6% Since JMP Securities Downgraded One Week Ago (SLXP) - Financial News Network Online

Few days ago at www.fnno.com

Salix Pharmaceuticals Up 2.6% Since JMP Securities Downgraded One Week Ago (SLXP)

A week ago, JMP Securities downgraded Salix Pharmaceuticals from Outperform to Market Perform. The shares closed at $47.29, or 2.6% over the $46.11 price of one week ago.

Few days ago at www.fnno.com

Salix Pharmaceuticals is Among the Companies in the Pharmaceuticals Industry ...

Salix Pharmaceuticals is Among the Companies in the Pharmaceuticals Industry ... Financial News Network Online - 10 hours ago We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength.

Few days ago at www.fnno.com